Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. - Wikidata - awgldk - TriplyDB

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

http://www.wikidata.org/entity/Q39254330

about

Technical challenges in the isolation and analysis of circulating tumor cells Evaluation and consequences of heterogeneity in the circulating tumor cell compartment When Prostate Cancer Circulates in the Bloodstream Circulating cancer stem cells: the importance to select Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles The promise of circulating tumor cell analysis in cancer management Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion Using circulating tumor cells to inform on prostate cancer biology and clinical utility Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA Microfluidic blood cell sorting: now and beyond.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.ERG induces taxane resistance in castration-resistant prostate cancer The link between androgen receptor splice variants and castration-resistant prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.Microfluidic, marker-free isolation of circulating tumor cells from blood samples Molecular pathways and targets in prostate cancer RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Constitutive activity of the androgen receptor.Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering.A microfluidic device for label-free, physical capture of circulating tumor cell clusters.Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients Advanced neuroendocrine prostate tumors regress to stemness Rare cell isolation and recovery on open-channel microfluidic chip.Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.Circulating tumor cells

P2860

Q26741646-6A98D53B-7865-47D7-8B2A-08F8C8675AF0 Q26765357-35A9B5E0-E806-41B0-9106-8237A48F87C4 Q26768470-A2E2E7B9-11A0-449A-A7E8-037D3B3880EE Q26778924-C07F1A4C-2934-42E1-AD59-ED1FF292CADA Q26865810-C2D0F34E-5CFF-4964-A4FA-AFCB7012FC3B Q27022113-857A5C9E-6563-4611-969B-D1E106998A7D Q27334142-9045EB6D-D7CC-46BD-ABA2-937B66A06E78 Q28066285-48A8980F-5C20-4952-8D7C-BDAF6B208792 Q28083261-9DD4995A-B44F-4644-8835-D336752EA485 Q28239638-80025DAB-CC1C-4361-94F7-637C6433B8E0 Q30412049-030AC901-590D-4D54-B6E6-5FCB29A34B0B Q30554439-B059A45F-5DCD-4263-839A-6D32AA887CEB Q30602046-8AA305C1-B7F7-4761-8ECD-9623B473ABB8 Q30618562-EA3F9AD8-4EB5-471D-B173-0BD5026D2A3D Q33621403-E5C4933A-394E-4DA8-8B7E-D6E99AE0B37F Q33883227-9DDB13B8-D7BE-49B4-8FE4-8C596D3EA14C Q33917455-FAA2C518-881A-440E-BBCD-23E1B85402EC Q33988851-F54B5343-D88B-4D4B-934E-4FECF2F779D0 Q34036427-03246E25-91B5-4FC4-89A2-26D40BB648C7 Q34096832-82175E23-2202-4695-91E7-361929C7C90E Q34108738-2CB50EE8-E305-4A1E-BEAB-05A3694BE0D7 Q34111187-09A1372C-2100-44CC-9DAE-55F01A8D8946 Q34263808-4548742A-CC5D-45F1-A488-D7EEEA99EE2F Q34365632-F21CF704-FB05-46BD-B756-D1F3509C001A Q34494714-A6A754D2-15A3-44EA-8E9A-F659E119ED5B Q34528225-EB7AF201-95FE-49B0-914F-C2F123D9DA52 Q34611922-8FEDC77B-9617-42E3-A618-F951F3C2DDBE Q34655256-92A31AD0-29E2-45F3-828F-691A9DC0959E Q34775572-4852FE3F-3D8F-4382-A139-BC0D5A70FB40 Q35543094-88E7C38A-60C6-4FF4-8B89-FA8CC1B7DB1C Q35655761-725AEB26-714F-421A-BB11-0BF5B0977C67 Q35755590-2C13EEA3-F8A1-4B34-A1D9-409713F83A4A Q35812039-1509E767-F7D0-4D71-97ED-14AEEB4692EA Q35956586-2C9F273A-C5F5-4E7C-8A83-B0BABAEE0C68 Q36004694-3C86C528-D1D3-4916-A7F8-79BF146F43EA Q36287422-1BF6CD85-71C1-43B7-9EFC-3C08B21576F1 Q36332128-2FC152B2-E68A-4195-AC75-46E37A44D30D Q36352034-D5CD4D37-6759-4531-AC72-5CBE5DED694C Q36373625-616BEC52-630D-4B9B-B8F9-77981698709F Q36729677-CA9A4D2D-4514-437C-BE47-B03580154E68

P2860

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

http://www.wikidata.org/entity/Q39254330

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Androgen receptor signaling in ...... ly responsive prostate cancer.

@en

Androgen receptor signaling in ...... ly responsive prostate cancer.

@nl

type

label

Androgen receptor signaling in ...... ly responsive prostate cancer.

@en

Androgen receptor signaling in ...... ly responsive prostate cancer.

@nl

prefLabel

Androgen receptor signaling in ...... ly responsive prostate cancer.

@en

Androgen receptor signaling in ...... ly responsive prostate cancer.

@nl

P1433

Q39254330-AACF3743-BEA8-460F-8A9B-B54BECA14BF0

P1476

Q39254330-C8C3907C-001C-42AF-97AF-3E2E655E106C

P2093

Q39254330-1F4E31FF-CE87-46C7-889C-6C37B2CC99F0

Q39254330-2DE73C41-6E66-411D-9335-FFBA7CE6052E

Q39254330-302394EF-E49C-4EB2-9D51-60F754285160

Q39254330-38F5FC22-1F8C-4E68-8114-CD73B64CB90B

Q39254330-3F0CAE2C-8038-407F-8679-4B41DBD58FEA

Q39254330-63296215-F197-4C6C-BDBC-6FA65CAC7AA9

Q39254330-6A6AF29A-5212-4D8A-8F7C-60BC80C74C7F

Q39254330-7CE03ADD-7B9E-444D-BBAB-27ECB7DE3505

Q39254330-829FB040-47D4-4265-8D46-8426900E019E

Q39254330-8622D7B0-D2C4-48FE-882A-32458B14C69D

P2860

Q39254330-007AAD5F-CDFC-4721-9626-6A3C9D65E98E

Q39254330-03B2E1B1-0063-41E1-A992-8CAC83695117

Q39254330-179DA3E5-28F6-482C-B97B-5171729F5675

Q39254330-1C43365C-7C4B-47D2-8826-830B6365D36F

Q39254330-3AABBE0B-F446-4B84-AA78-AB597CCC2791

Q39254330-54BF47FE-07C5-4263-A43F-9B8623CD2F73

Q39254330-59B3636A-8CEB-4027-ACCA-F5810A21E84C

Q39254330-6411A9B5-91F5-4315-A9AF-A7B4B4AD078A

Q39254330-6B021E09-2AF5-4059-97CD-BC15F260765D

Q39254330-71079AF3-489C-4269-AA26-1140E0810FC7

P304

Q39254330-1ABBC38D-0E73-46CE-80A6-C68CDCB55B32

P31

Q39254330-C2DE2657-0F29-4709-9E5B-DE0816906B7E

P356

Q39254330-B7013117-5E8D-4626-8FC3-E1A899109B11

P433

Q39254330-5FD3EF1D-CEB5-49DC-A334-4B1F11AAFD4B

P478

Q39254330-F31B2303-6754-42A3-8CDB-B73D9AE03B7F

P50

Q39254330-4304ADCE-46F0-4E12-9B4D-CEEB0B73DDCB

P577

Q39254330-35776109-AA36-454F-8961-1210E4459B6F

P698

Q39254330-53DE65A2-2EB5-4AC4-A710-AF4CC7CA08C4

P932

Q39254330-5DABADAD-6157-460D-8E5B-E5274BED26F9

P356

2159-8290.CD-12-0222

P1433

Cancer Discovery

P1476

Androgen receptor signaling in ...... lly responsive prostate cancer

@en

P2093

Ben S Wittner

http://www.w3.org/2001/XMLSchema#string

Brian W Brannigan

http://www.w3.org/2001/XMLSchema#string

Chin-Lee Wu

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

David T Miyamoto

http://www.w3.org/2001/XMLSchema#string

Jenna B Lord

http://www.w3.org/2001/XMLSchema#string

Julie Trautwein

http://www.w3.org/2001/XMLSchema#string

Lecia V Sequist

http://www.w3.org/2001/XMLSchema#string

Malgorzata E Smas

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device

Abiraterone and increased survival in metastatic prostate cancer

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

P304

995-1003

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-12-0222

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23093251

http://www.w3.org/2001/XMLSchema#string

P932

3508523

http://www.w3.org/2001/XMLSchema#string